Search

Now showing items 21-30 of 127

Validation of an environmentally-friendly and affordable cardboard 9-hole peg test.

Dubuisson, N; Bauer, A; Buckley, M; Gilbert, R; Paterson, A; Marta, M; Gnanapavan, S; Turner, B; Baker, D; Giovannoni, G;... (2017-10)

BACKGROUND: In multiple sclerosis (MS) upper limb neurological impairments, are an important driver of disability and handicap. The gold standard for assessing upper limb function is the 9-hole peg test (9HPT). One ...

Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids

Pryce, G; Riddall, DR; Selwood, DL; Giovannoni, G; Baker, D (2015-12-24)

© 2014, Springer Science+Business Media New York. Multiple sclerosis (MS) is the major immune-mediated, demyelinating, neurodegenerative disease of the central nervous system. Compounds within cannabis, notably ...

Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab

Baker, D; Herrod, SS; Alvarez-Gonzalez, C; Giovannoni, G; Schmierer, K (2017-08)

CANCER RISK IN MULTIPLE SCLEROSIS PATIENTS TAKING CLADRIBINE

Pakpoor, J; Disanto, G; Altmann, DR; Pavitt, S; Turner, B; Calado-Marta, M; Juliusson, G; Baker, D; Chataway, J; Schmierer, K (2014-10)

Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis

von Kutzleben, S; Pryce, G; Giovannoni, G; Baker, D (2017-04)

1
2
3
4
5
6
. . .
13

Search

Validation of an environmentally-friendly and affordable cardboard 9-hole peg test.

Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids

Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab

CANCER RISK IN MULTIPLE SCLEROSIS PATIENTS TAKING CLADRIBINE

Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis

Disease modification in advanced MS: Focus on upper limb function.

No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.

Simvastatin in patients with progressive multiple sclerosis

Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis

Characterization of immune response to neurofilament light in experimental autoimmune encephalomyelitis

Search

Filters

Validation of an environmentally-friendly and affordable cardboard 9-hole peg test.

Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids

Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab

CANCER RISK IN MULTIPLE SCLEROSIS PATIENTS TAKING CLADRIBINE

Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis

Disease modification in advanced MS: Focus on upper limb function.

No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.

Simvastatin in patients with progressive multiple sclerosis

Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis

Characterization of immune response to neurofilament light in experimental autoimmune encephalomyelitis